Contineum Therapeutics, Inc.

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for neuroinflammation and immunology (NI&I) indications with significant unmet need. Its lead programs are PIPE-791 for chronic pain and PIPE-307 for depression, with PIPE-307 being advanced in collaboration with Johnson & Johnson.

27.50

27.50

— Contineum Therapeutics, Inc.
%
Clinical-stage drug candidates0% Lead therapeutic programs in development, including PIPE-791 and PIPE-307.
Collaboration revenue100% License and milestone economics tied to the J&J agreement for PIPE-307.
Research and development pipeline0% Internal discovery and preclinical work supporting future NI&I indications.

Contineum does not sell approved commercial products today; its current counterparties are primarily development...

  • Strategic collaboration partnerprimary

    Johnson & Johnson funds and supports PIPE-307 development under the license agreement.

  • Clinical development ecosystemprimary

    CROs, investigators, laboratories, and CMOs that execute trials and manufacture clinical supply.

  • Regulatory authoritiesprimary

    FDA and comparable agencies that review safety, efficacy, and manufacturing readiness.

  • Future patients and payorsemerging

    Patients with chronic pain or depression and the insurers that would reimburse approved therapies.

Contineum is headquartered in San Diego, California, and its operating footprint is centered in the United States...

  • •Headquartered in San Diego, California
  • •Office and laboratory space concentrated in the U.S.
  • •Clinical development and regulatory work are U.S.-centric
  • •No disclosed country revenue mix because there is no product sales base
  • •Future commercialization could expand beyond the U.S. if approved

Contineum’s strategy is to advance a focused pipeline of selective small molecules for NI&I diseases, using PIPE-791...

01
Advance clinical programsshort-term

Pipeline value depends on successful clinical data and regulatory milestones.

02
Secure financingshort-term

The company expects operating expenses to rise materially as trials expand.

03
Build IP and development infrastructuremedium-term

Patent protection and operational readiness are essential before commercialization.

Contineum is highly dependent on two early-stage drug candidates, so clinical setbacks, safety issues, or regulatory...

critical

Pipeline concentration

The company is heavily dependent on two early-stage assets, so any failure would materially reduce prospects.

Scope
PIPE-791 and PIPE-307
Materiality
high
high

Clinical and regulatory failure

Drug candidates may not demonstrate efficacy, safety, or approvability in trials.

Scope
Phase 1/2 and later-stage development
Materiality
high
high

Financing and dilution

Operating losses and trial costs require ongoing capital raises before any product revenue exists.

Scope
ATM, follow-on equity, future fundraises
Materiality
high
medium

Manufacturing and supply chain

Clinical and future commercial supply depends on qualified third-party manufacturers and compliant facilities.

Scope
CMOs, clinical supply, BIOSECURE-related constraints
Materiality
medium
medium

Competitive and reimbursement pressure

Approved therapies for pain and depression include generics and established branded drugs, limiting pricing power.

Scope
Future commercialization
Materiality
medium
License revenue recognition
Milestone timing can create lumpy quarterly revenue
R&D accruals
Changes in trial activity can shift expense recognition between periods
Stock-based compensation
Can materially affect operating expense and reported losses
Fair value measurements
Important around financing events and equity issuances
Lease commitments
Affects balance sheet liabilities and operating cash commitments

Context Therapeutics Inc.

CNTX · Pharmaceutical Preparations

Gain Therapeutics, Inc.

GANX · Pharmaceutical Preparations

CNS Pharmaceuticals, Inc.

CNSP · Pharmaceutical Preparations

Vistagen Therapeutics, Inc.

VTGN · Pharmaceutical Preparations

Equillium, Inc.

EQ · Pharmaceutical Preparations

Cullinan Therapeutics, Inc.

CGEM · Biological Products, (No Diagnostic Substances)

: 28/04/2026